Henrik Agersø

Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration

Lotte Bjerre Knudsen, Per F. Nielsen, Per Olaf Huusfeldt et al. · Journal of Medicinal Chemistry · 2000 · 681 citations · Full text

Peptide Engineering, Glycobiology, Once Daily Administration +21

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men

Henrik Agersø, Lene Jensen, B. Elbrønd et al. · Diabetologia · 2002 · 503 citations · Full text

Physiology, Pharmacology, Clinical Pharmacology +5

Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy Subjects

Tina Vilsbøll, Henrik Agersø, Thure Krarup et al. · The Journal of Clinical Endocrinology & Metabolism · 2003 · 437 citations · Full text

Nutrition, Healthy Subjects, Insulin Signaling +20

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects

B. Elbrønd, Grethe Jakobsen, Søren Erik Larsen et al. · Diabetes Care · 2002 · 282 citations · Full text

Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes

Claus Bogh Juhl, Malene Hollingdal, Jeppe Sturis et al. · Diabetes · 2002 · 266 citations · Full text